Agila Biotech to invest $34.4 mn in Malaysia

With this investments Agila Biotech (Malaysia) joins Biocon (India), MetE x (France) and Glycos Biotechnologies (USA) as the early entrants into the Bio-Xcell ecosystem


Bio-Xcell - Attracting investments to Malaysia

Agila Biotech, a Strides Acrolab Ltd (Strides) enterprise announced that Agila Biotech Sdn Bhd (Agila Biotech (Malaysia)) - its wholly owned subsidiary has entered into an agreement with Malaysian Bio-Xcell, a biotechnology park and ecosystem dedicated to healthcare and industrial biotechnology. With this deal Agila Biotech (Malaysia) joins Biocon (India), MetE x (France) and Glycos Biotechnologies (USA) as the early entrants into the Bio-Xcell ecosystem.

The $34.4 million (RM107 million ) Build-and-Lease Agreement is for the establishment of a customized biotech facility located in the Bio-Xcell ecosystem in Nusajaya, Johor, Malaysia. The agreement will replace an earlier agreement signed in May 2011. The deal was signed between En. Rizatuddin Ram li, CEO of Bio-Xcell and Dr. Anand Iyer, CEO of Agila Biotech (Malaysia) a subsidiary of India-listed Strides Arcolab Ltd at the three day BioPharma Asia Convention (BioPharma Asia) happening in Singapore from March 19, 2013.

Agila Biotech (Malaysia) has plans to develop a state-of-the-art, multi-product, scalable manufacturing facility with a production capacity for mammalian (2KL expandable up to 8KL) and microbial (500 L expandable up to 2KL) products. It also aims to develop advanced formulation/ fill finish facilities to meet Agila Biotech (Malaysia)'s business model which will support the manufacturing of internal pipeline products as well as CMO activities. These facilities will be able to support the production of Recombinant Monoclonal Antibodies (mAbs) from DS to DP, Recombi nant Therapeutic Proteins from DS to DP, CMO activities for DS and DP, chemistry and for mulation activities for PEGylation, novel formulation development and sterile fill finish facilities for vials, PFS, cartridges and lyophilized products.

"Agila Biotech (Malaysia) is indeed poised to be a major anchor tenant for the Bio-Xcell ecosystem and we are extremely pleased to be able to offer our services and support for this promising project," said Mr Rizatuddin Ramli. Bio- Xcell will fund RM67.32 million (approximately $22 million) to be provided under the Build-and-Lease Agreement with Agila Biotech (Malaysia), which will cover the construction of the building and part of the equipment. All other related state-of-the-art equipment, integration service and testing of this turnkey project (estimated at $13-15 million) will be funded by Agila Biotech (Malaysia) from internal accruals and funding from external sources."

The work on the facility for the end-to-end manufacturing of biologics located on an 8.77 acre plot is expected to start as soon as all necessary clear nces and permits have been obtained and all supplemental agreements have been executed. Both p rties are aiming for the R&D and manufacturing facilities to be operational by end 2014.

Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email